Enanta's lung infection therapy succeeds in mid-stage trial
Enanta Pharmaceuticals Inc said on Friday its treatment for a highly contagious respiratory infection met the main goal of reducing virus levels in the body and improving symptoms in patients in a mid-stage study.
from Reuters: Health News https://reut.rs/2MIAVuX
http://bit.ly/2zwRqiM
June 14, 2019
|
Labels:
health,
Reuters: Health News
|
This entry was posted on June 14, 2019
and is filed under
health
,
Reuters: Health News
.
You can follow any responses to this entry through
the RSS 2.0 feed.
or trackback from your own site.